<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299168</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC-001</org_study_id>
    <nct_id>NCT01299168</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation</brief_title>
  <official_title>Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard for biopsy-based diagnoses of dysfunction of kidney transplants is the
      Banff Classification which represents arbitrary international consensus. Recent data-driven
      approaches using molecular and conventional technologies indicate that mere consensus
      produces frequently incorrect diagnoses with potential harm to patients due to inappropriate
      treatment. To address this unmet need and improve diagnostics in the area of organ
      transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC) has developed a new
      diagnostic system that combines the molecular and histopathological features of transplant
      biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic
      System. The present study will validate and refine this system in 500 prospectively
      unselected biopsies for clinical indications from American, Canadian and European centres in
      addition to 300 biopsies already collected. Due to a considerable interest and support from
      participating Centers, the study is further extended to 1200 prospective biopsies. Thus this
      is the extension of the INTERCOM study (INTERCOMEX). In addition to demonstrating the
      feasibility and value of this System in routine patient care and clinical trials, the study
      will develop and optimize a transparent and user-friendly reporting format to communicate
      this information to clinicians and obtain detailed feedback on how this system can best
      improve patient care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is now enrolling (N=1100) and the results were analyzed for the first 300 collected
      biopsies. Follow-up data is, and will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the Integrated Diagnostic System in the International Collaborative Microarray (INTERCOM) Study</measure>
    <time_frame>2013-2016</time_frame>
    <description>The rejection classifier predicts Banff diagnosis of any rejection: ABMR, TCMR, or mixed ABMR and TCMR;
The TCMR classifier predicts the presence of Banff TCMR lesions/diagnoses;
The ABMR classifier predicts the presence of ABMR lesions;
In late (&gt;1yr) biopsies for clinical indications, the failure classifier predicts failure within three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate the feasibility of molecular phenotyping of 300 + 500 kidney transplant biopsies for clinical indications.</measure>
    <time_frame>2014-2016</time_frame>
    <description>To test the hypothesis that the molecular phenotype of a newly acquired sample predicts the histologic and clinical features of this sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate the feasibility of molecular phenotyping of 500 biopsies in real time i.e. returning the molecular phenotyping report in two working days upon sample arrival.</measure>
    <time_frame>2015-2016</time_frame>
    <description>Refine the reports based on feedback from the participants.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Validation Study of Molecular Diagnostic System</condition>
  <condition>Development of Reporting System for Molecular Diagnosis</condition>
  <condition>Incorporate Molecular Diagnosis Into Diagnostic Standards</condition>
  <arm_group>
    <arm_group_label>Kidney Transplant Biopsies for Cause</arm_group_label>
    <description>The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Needle kidney biopsy core as per local standard of care
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients with a functioning kidney transplant undergoing a
        biopsy for clinicalindications as standard of care to determine the cause of their graft
        dysfunction (deterioration in graft function, delayed graft function, proteinuria).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All kidney transplant recipients ≥18yrs of age undergoing a kidney biopsy for clinical
             indications, as determined by their physician or surgeon, will be eligible to enrol in
             the study.

        Exclusion Criteria:

          -  Patients will be excluded from the study if they decline participation or are unable
             to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <phone>1 780 492-6160</phone>
    <email>phallora@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konrad S Famulski, PhD DSc</last_name>
    <phone>1 780 4921725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>MI 48109-5395</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>MO 63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Transplant Associates</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute - Methodist Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University School of Medicine</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaurav Gupta, MD</last_name>
      <email>ggupta@mcvh-vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Baldecchi</last_name>
      <email>mbaldecchi@mcvh-vcu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gaurav Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>WI 53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Boehmig, MD PhD</last_name>
      <email>georg.boehmig@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Farsad Eskandry, MD</last_name>
      <email>farsad.eskandary@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Georg Boehmig, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farsad Eskandry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2S2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soroush Shojai, MD</last_name>
      <email>shojai@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Soroush Shojai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, University of Usan, College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Shin, MD PhD</last_name>
      <phone>82 2 3010 3964</phone>
      <email>sshin@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Sung Shin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pomeranian Medical University in Szczecin</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016 Sep;12(9):534-48. doi: 10.1038/nrneph.2016.85. Epub 2016 Jun 27. Review.</citation>
    <PMID>27345248</PMID>
  </reference>
  <results_reference>
    <citation>Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant. 2013 Sep;13(9):2352-63. doi: 10.1111/ajt.12387. Epub 2013 Aug 5.</citation>
    <PMID>23915426</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J. Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am J Transplant. 2013 Nov;13(11):2865-74. doi: 10.1111/ajt.12465. Epub 2013 Oct 3.</citation>
    <PMID>24119109</PMID>
  </results_reference>
  <results_reference>
    <citation>Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014 Oct;25(10):2267-77. doi: 10.1681/ASN.2013111149. Epub 2014 Apr 3.</citation>
    <PMID>24700874</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J. Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol. 2015 Jul;26(7):1711-20. doi: 10.1681/ASN.2014060588. Epub 2014 Nov 6.</citation>
    <PMID>25377077</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Merino Lopez M, Barreto Pereira A. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants. Am J Transplant. 2016 Mar;16(3):908-20. doi: 10.1111/ajt.13551. Epub 2016 Jan 6.</citation>
    <PMID>26743766</PMID>
  </results_reference>
  <results_reference>
    <citation>Reeve J, Chang J, Salazar ID, Lopez MM, Halloran PF. Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection. Am J Transplant. 2016 Apr;16(4):1183-92. doi: 10.1111/ajt.13572. Epub 2016 Jan 5.</citation>
    <PMID>26730747</PMID>
  </results_reference>
  <results_reference>
    <citation>Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, Kikić Ž, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, König F, Hidalgo LG, Oberbauer R, Halloran PF, Böhmig GA. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplantation. 2017 Mar;101(3):631-641. doi: 10.1097/TP.0000000000001195.</citation>
    <PMID>27120452</PMID>
  </results_reference>
  <results_reference>
    <citation>Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol. 2017 Jun;28(6):1912-1923. doi: 10.1681/ASN.2016070797. Epub 2017 Mar 2.</citation>
    <PMID>28255002</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Am J Transplant. 2017 Nov;17(11):2851-2862. doi: 10.1111/ajt.14329. Epub 2017 May 30.</citation>
    <PMID>28449409</PMID>
  </results_reference>
  <results_reference>
    <citation>Reeve J, Böhmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, Halloran PF; MMDx-Kidney study group. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017 Jun 15;2(12). pii: 94197. doi: 10.1172/jci.insight.94197. [Epub ahead of print]</citation>
    <PMID>28614805</PMID>
  </results_reference>
  <results_reference>
    <citation>Madill-Thomsen KS, Wiggins RC, Eskandary F, Böhmig GA, Halloran PF. The Effect of Cortex/Medulla Proportions on Molecular Diagnoses in Kidney Transplant Biopsies: Rejection and Injury Can Be Assessed in Medulla. Am J Transplant. 2017 Aug;17(8):2117-2128. doi: 10.1111/ajt.14233. Epub 2017 Mar 23.</citation>
    <PMID>28226404</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Venner JM, Famulski KS. Comprehensive Analysis of Transcript Changes Associated With Allograft Rejection: Combining Universal and Selective Features. Am J Transplant. 2017 Jul;17(7):1754-1769. doi: 10.1111/ajt.14200. Epub 2017 Feb 25.</citation>
    <PMID>28101959</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Philip Halloran</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>global gene expression</keyword>
  <keyword>molecular diagnostic classifiers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

